Alendronate Sodium
Product Images NDC 68071-4120

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 68071-4120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 4120 01 A161)

Label for Alendronate Sodium 70mg tablets from NuCare Pharmaceuticals, Inc. The label includes the product name, strength, dosage form, manufacturer, NDC 68071-4120-1, warnings to keep out of reach of children, and storage instructions at controlled temperature 59-86°F. It also states Rx only and includes multiple mentions of product lot number and expiration date placeholders.*

FDA Label Image

Structural Formula For Alendronate Sodium (Alendronate Sodium Tablets 3)

Chemical structure of alendronate sodium, showing its molecular framework with phosphorus, oxygen, carbon, and nitrogen atoms, including three water molecules of hydration (3H2O).*

FDA Label Image

Cumulative Incidence Of Hip Fractures In The Three-year Study Of Fit (patients With Radiographic Vertebral Fracture At Baseline) (Alendronate Sodium Tablets 4)

A line graph comparing cumulative incidence (%) over time (months) between alendronate sodium and placebo groups. The x-axis represents time from 0 to 36 months, and the y-axis shows cumulative incidence up to 10%. The graph shows lower cumulative incidence for alendronate sodium compared to placebo throughout the time period.*

FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Increase In Bmd Alendronate Sodium 10 mg/day At Three Years (Alendronate Sodium Tablets 5)

A bar chart comparing bone mineral density (BMD) mean percent increase relative to placebo with standard error in three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter. The chart shows data for two groups, labeled U.S. and Multinational, with U.S. values represented by diagonally striped bars and Multinational by solid gray bars.*

FDA Label Image

Osteoporosis Treatment Studies In Postmenopausal Women Time Course Of Effect Of Alendronate Sodium 10 mg/day Versus Placebo: Lumbar Spine Bmd Percent Change From Baseline (Alendronate Sodium Tablets 6)

Two line graphs comparing mean percent change in bone mineral density (BMD) from baseline over 36 months for alendronate sodium 10 mg versus placebo. The left graph shows results from a U.S. study and the right from a multinational study. Both graphs indicate increased BMD with alendronate sodium compared to placebo, which remains near zero throughout the time course.*

FDA Label Image

Osteoporosis Prevention Studies In Postmenopausal Women (Alendronate Sodium Tablets 7)

Two bar graphs showing the change in bone mineral density (BMD) from baseline comparing alendronate sodium 5 mg/day and placebo over 2- and 3-year studies. The graphs depict mean percentage change plus standard error across four body regions: lumbar spine, femoral neck, trochanter, and total body.*

FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate Sodium 5 mg/day at One Year)

A bar graph comparing the percentage increase in bone mineral density (BMD) at three bone sites—lumbar spine, femoral neck, and trochanter—between U.S. and multinational study groups. The vertical axis represents BMD increase percentages with error bars showing standard error.*

FDA Label Image

Studies In Paget’s Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate Sodium 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Sodium Tablets 9)

A line graph depicting the mean percentage change from baseline in serum alkaline phosphatase over 6 months. It compares placebo, etidronate 400 mg/day, alendronate sodium 40 mg/day from a multinational study, and alendronate sodium 40 mg/day from a U.S. study. Data points include sample sizes and error bars.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.